Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
23,551 total articles
Decoy Therapeutics, a NASDAQ-listed biotechnology company specializing in designing multi-antiviral peptides across viral families, announced that CEO Rick Pierce will present at The Small Cap Showcase in New York City. The presentation will cover corporate overview and investor meetings, highlighting their AI-driven IMP³ACT platform and lead antiv…
AIB Data Centers Inc. has signed a binding agreement with Nebius for 50 MW of critical IT capacity at its southeastern U.S. data center. The deal includes long-term customer prepayments and financing, reducing equity dilution risk, and leverages existing electrical infrastructure to deploy AI-focused data halls efficiently. This marks a significant…
Regency Centers Corporation, a leading national REIT specializing in shopping centers, will release its third quarter 2026 earnings after market close on November 5, 2026, followed by a conference call on November 6, 2026.
Foresight Autonomous Holdings Ltd. announced its decision to voluntarily delist its ordinary shares from the Tel Aviv Stock Exchange (TASE) effective January 4, 2027, while continuing to trade its American Depositary Shares (ADSs) on the Nasdaq under ticker FRSX. This move aims to reduce costs and administrative complexity associated with dual list…
Terra Innovatum Global N.V. (NASDAQ: NKLR), a developer of advanced micro-modular nuclear reactors, announced upcoming participation in three major investor conferences to discuss progress in licensing, industrialization, and commercialization of its SOLO™ micro-modular reactor. The company is advancing its Nuclear Regulatory Commission licensing p…
Candel Therapeutics presented biomarker data from its phase 3 trial of aglatimagene besadenovec showing significant and sustained immune remodeling in patients with localized intermediate- to high-risk prostate cancer over two years following treatment combined with radiation. The AI-enabled analysis showed increased lymphocyte infiltration and tum…
Ardelyx, a US-based biopharmaceutical company, received multiple honors at the 2026 PM360 Trailblazer Awards, including CEO of the Year for Mike Raab, a Gold Award for its podcast 'Gut Matters,' and a Silver Award for the IBSRELA marketing team. These awards recognize Ardelyx's growth, innovation, patient-focused initiatives, and leadership in the …
Esperion Therapeutics, wholly owned by ARCHIMED, is rolling out ENBUMYST, an intranasal bumetanide nasal spray for short-term treatment of edema in heart failure patients. This new administration route offers a non-invasive alternative to IV diuretics and aligns with upcoming CMS Ambulatory Specialty Model payment reforms starting 2027. Esperion ai…
NuCana plc announced that the European Patent Office has granted a key composition-of-matter patent for its novel anti-cancer agent NUC-7738, reinforcing its intellectual property protection across major markets. This milestone advances NuCana's long-term commercial strategy and supports ongoing Phase 1/2 clinical trials combining NUC-7738 with pem…
CTS Corporation has introduced its first Digital Temperature Sensor platform, expanding its portfolio with high-accuracy digital sensing solutions designed for industrial, medical, transportation, and electronics sectors. This new platform offers precise temperature measurement with digital communication capabilities, multiple probe styles, and sim…
AEON Biopharma announced that the FDA's Type 2b meeting provided constructive feedback on the development of ABP-450, its biosimilar to BOTOX®, indicating acceptance of previously completed comparative studies as supportive evidence and endorsing a comparative pharmacodynamic study design. The company plans to submit an IND for the pharmacodynamic …
Silexion Therapeutics has dosed the first patient in its global Phase 2/3 clinical trial evaluating SIL204, an RNAi therapeutic for KRAS-mutated locally advanced pancreatic cancer. The study combines direct intratumoral and subcutaneous delivery with standard chemotherapy to improve treatment efficacy. The trial initiated at Tel Aviv Sourasky Medic…
Trio Petroleum Corp announced that its Canadian subsidiary acquired 24 oil wells from Marlin Resources in Saskatchewan's Lloydminster region, including 4 producing and 20 shut-in heavy-oil wells. The deal incorporates production of approximately 37 barrels of oil per day with significant upside from a proposed Cummings multilateral well and workove…
Eupraxia Pharmaceuticals announced promising 52-week Phase 1b/2a RESOLVE trial results for EP-104GI, showing sustained clinical remission and histologic improvements in patients with Eosinophilic Esophagitis (EoE) after a single dose. The treatment demonstrated favorable safety with no serious adverse events, supporting potential for a once-annual …
Immutep Limited, a late-stage immunotherapy biotech firm, has received approximately A$856,669 from the Australian Federal Government's R&D tax incentive program for its 2025 fiscal year expenditures. The funding, including additional French and German tax incentives, supports the advancement of its cancer and autoimmune disease therapies, notably …
Rank One Computing Corporation (ROC) announced its ROC-003 algorithm secured the top global position for age estimation accuracy across three primary datasets in the National Institute of Standards and Technology (NIST) Face Analysis Technology Evaluation for Age Estimation and Verification (FATE AEV). This achievement solidifies ROC's transition f…
Celcuity Inc. announced that its drug REVTORPYK (gedatolisib) is now commercially available in the United States for treatment of hormone receptor-positive, HER2-negative advanced breast cancer patients without PIK3CA mutation, following progression on endocrine therapy. REVTORPYK, a first-in-class inhibitor of all class I PI3K isoforms and mTOR co…
Banzai International, Inc. (Parabolic) has executed initiatives following its ConnectAndSell acquisition that are expected to yield approximately $9.3 million in annualized cost savings. These savings come from workforce reductions, minimized third-party contractor use, and the implementation of a new business unit operating model aimed at improvin…
Tokyo Lifestyle Co., Ltd. announced a year-end cash dividend of JPY 1.890 per share for the fiscal year ending March 31, 2026, highlighting its focus on shareholder returns while balancing capital allocation and long-term growth. The company intends to continue prudent capital management to support sustainable business growth and value creation for…
California BanCorp, the holding company for California Bank of Commerce, announced it will open a new commercial loan production office in downtown San Francisco to strengthen its presence and service offerings in the Bay Area, reflecting its commitment to strategic growth in Northern California.
Integer Holdings Corporation announced early termination of the Hart-Scott-Rodino waiting period necessary for the acquisition by KKR affiliates at $127 per share, valuing the deal at approximately $5.7 billion. The transaction awaits stockholder approval and other customary closing conditions, with completion expected by the end of 2026.
Cycurion, Inc. announced its largest contract award to date, a $54.6 million 10-year engagement supporting the modernization of a major state Health and Human Services system. The company also completed the acquisition of Digital Ally's Video Solutions business, expanding its public safety portfolio and recurring revenue base. CEO L. Kevin Kelly em…
Verrica Pharmaceuticals announced they will present new analysis from Phase 3 trials indicating their FDA-approved drug YCANTH (VP-102) clears molluscum contagiosum lesions approximately four times faster than vehicle, regardless of disease duration. Additional data on investigational drug VP-315 for skin cancer will also be showcased. The clinical…
BioStem Technologies, a Nasdaq-listed regenerative medicine company, announced a private placement of 735,296 shares and warrants priced at-the-market, expected to raise approximately $3 million before fees. The funds will be used for working capital and general corporate purposes. Warrants issued could provide additional proceeds if exercised, tho…
Ten-League International Holdings Limited reported its unaudited financial results for the first six months of fiscal year 2026, showing total revenues of S$33.1 million (US$25.6 million) with a significant shift towards higher-value engineering consultancy services and rental income representing 45.4% of total revenue compared to 18.5% last year. …
